AstraZeneca CEO not signing UK govt Brexit letter

Deep uncertainty about future terms of trade just 18 months before Brexit happens in March 2019

Initiate suitable prosecution steps against AstraZeneca management, pleads FMRI
Reuters Madrid
Last Updated : Sep 11 2017 | 2:52 AM IST

AstraZeneca Chief Executive Pascal Soriot, fearing a potentially abrupt Brexit, said on Saturday that lack of progress in negotiations made it impossible for him to sign a public letter of support for the British government's strategy.

As reported by Reuters this week, Prime Minister Theresa May's office has asked companies listed in the blue-chip FTSE 100 index to put their name to a public letter welcoming the government's efforts to make Brexit a success.

"The reason I didn't sign is that I felt there are so many areas that are still uncertain. How can we support something that we don't really understand fully?" Soriot told Reuters on the sidelines of a cancer conference in Madrid.

Executives at several companies have said privately that the request went down badly with many large corporations but they have been reluctant to comment publicly.

Soriot said his refusal to sign did not mean the drugmaker disagreed with Britain's decision to leave the European Union, adding that it could have some positive aspects if it went hand-in-hand with increased support for the UK life sciences sector.

But the deep uncertainty about future terms of trade just 18 months before Brexit happens in March 2019 means exports of medicines could be hampered, he said.

"What is starting to worry me, I must say, is the potential for the one thing I didn't think would happen which is a hard Brexit," he said.

"If there is no extension we will be left in limbo because the UK will come out of Europe and we will have no trade agreements."

Britain's second-biggest pharmaceuticals company makes a lot of products in the north of England, including the cancer drug Zoladex, sales of which are increasing rapidly in China and other countries around the world.

"We need to know that is not going to be disrupted because right now we are exporting under a trade agreement between the EU and China," Soriot said.

Many companies fear that Britain's move to leave the world's largest trading bloc will increase bureaucracy, drive up costs and eat into profitability.

The public letter, which May's advisers wanted Soriot and other business leaders to sign, states that signatories are confident that "global Britain has the potential to become one of the most productive economies of the 21st century".

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 11 2017 | 2:52 AM IST

Next Story